注册
CN
科译新闻资讯



当前位置: 首页 >> 新闻资讯>> 新闻详情

EFSA:一种6'-唾液乳糖钠盐作为新型食品的安全性

文章来源: 作者: 发布日期:2022-12-19 浏览次数: 697 次
       2022年12月7日,据欧盟食品安全局EFSA)消息,欧盟营养、新型食品和食物源(NDA)研究小组就一种6'-唾液钠盐(6′-sialyllactose (6’-SL) sodium salt)作为新型食品的安全性发表科学意见。
 
  据了解,该6'-唾液乳糖钠盐是由大肠杆菌BL21 (DE3)的衍生菌株生产的。经过评估,专家小组得出结论,在提议的使用条件下,6'-唾液乳糖钠盐作为新型食品是安全的。部分原文报道如下:
 
  Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on 6′-sialyllactose (6’-SL) sodium salt as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is mainly composed of the human-identical milk oligosaccharide (HiMO) 6’-SL, but it also contains d-lactose, 6′-sialyllactulose, sialic acid, N-acetyl-d-glucosamine and a small fraction of other related oligosaccharides. The NF is produced by fermentation with two genetically modified strains of Escherichia coli BL21 (DE3), the production strain and the optional degradation strain. The information provided on the identity, manufacturing process, composition and specifications of the NF does not raise safety concerns. The applicant intends to add the NF to a variety of foods, including infant formula and follow-on formula, food for special medical purposes and food supplements. The target population is the general population. In some scenarios at the maximum use levels, the estimated intakes per kg body weight were higher than the high average natural intake of 6’-SL from human milk. However, given the intrinsic nature of human milk oligosaccharides (HMOs), the wide range of intakes from human milk, and considering that infants are naturally exposed to similar amounts of these substances, the Panel considers that the consumption of the NF at the proposed conditions of use does not raise safety concerns. The intake of 6’-SL in breastfed infants on a body weight basis is also expected to be safe for other population groups. The intake of other carbohydrate-type compounds structurally related to 6’-SL is also considered of no safety concern. Food supplements are not intended to be used if other foods with added 6’-SL or human milk are consumed on the same day. The Panel concludes that the NF is safe under the proposed conditions of use.

热门资讯

EFSA:一种6'-唾液乳糖钠盐作为新型食品的安全性
文章来源: 作者: 发布日期:2022-12-19 浏览次数: 697 次
       2022年12月7日,据欧盟食品安全局EFSA)消息,欧盟营养、新型食品和食物源(NDA)研究小组就一种6'-唾液钠盐(6′-sialyllactose (6’-SL) sodium salt)作为新型食品的安全性发表科学意见。
 
  据了解,该6'-唾液乳糖钠盐是由大肠杆菌BL21 (DE3)的衍生菌株生产的。经过评估,专家小组得出结论,在提议的使用条件下,6'-唾液乳糖钠盐作为新型食品是安全的。部分原文报道如下:
 
  Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on 6′-sialyllactose (6’-SL) sodium salt as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is mainly composed of the human-identical milk oligosaccharide (HiMO) 6’-SL, but it also contains d-lactose, 6′-sialyllactulose, sialic acid, N-acetyl-d-glucosamine and a small fraction of other related oligosaccharides. The NF is produced by fermentation with two genetically modified strains of Escherichia coli BL21 (DE3), the production strain and the optional degradation strain. The information provided on the identity, manufacturing process, composition and specifications of the NF does not raise safety concerns. The applicant intends to add the NF to a variety of foods, including infant formula and follow-on formula, food for special medical purposes and food supplements. The target population is the general population. In some scenarios at the maximum use levels, the estimated intakes per kg body weight were higher than the high average natural intake of 6’-SL from human milk. However, given the intrinsic nature of human milk oligosaccharides (HMOs), the wide range of intakes from human milk, and considering that infants are naturally exposed to similar amounts of these substances, the Panel considers that the consumption of the NF at the proposed conditions of use does not raise safety concerns. The intake of 6’-SL in breastfed infants on a body weight basis is also expected to be safe for other population groups. The intake of other carbohydrate-type compounds structurally related to 6’-SL is also considered of no safety concern. Food supplements are not intended to be used if other foods with added 6’-SL or human milk are consumed on the same day. The Panel concludes that the NF is safe under the proposed conditions of use.
我们的优势
16年医疗、知识产权领域翻译经验
16年医疗、知识产权领域翻译经验
自成立以来,CODEX 一直深耕医疗、知识产权领域翻译,高品质的翻译和服务,是CODEX得以持续发展的源动力。
专业的精英团队
专业的精英团队
CODEX的团队是由留学归国人员、重点高校毕业的研究生、专业的母语籍译员以及医学行业的专家顾问组成。
权威的质量认证体系
权威的质量认证体系
通过国际ISO17100:2015,ISO18587:2017, ISO9001:2015, ISO14001:2015, ISO 13485:2016等多项通过国际级别认证,服务多家国际著名的医药企业。
严格的管控流程
严格的管控流程
CODEX制定了完善的翻译质量保证体系和系统化的运作流程,严格采取一译、二改、三校、四审的工作程序。
绝佳的员工素质
绝佳的员工素质
我们中的每一位都经过严格的考核和挑选,精通医学翻译工作,形象佳责任心强,并严格遵循保密制度。
客户支持
客户支持
“精益求精,至善至美”科译质量和实力以及严格的保密制度倾心为您服务。
联系我们
CODEX科译在您身边

北京科译翻译有限公司

400-136-8786

我们将全天候为您服务
我们是谁
16年来,CODEX是一直致力于提供生命科学翻译和本地化服务的公司,是国内为数不多的通过国家ISO17100:2015认证的医学翻译提供商。
会员注册
发送验证码
注册
已有账号?点击登录
账号登录
短信登录
登录
没有账号?点击注册
发送验证码
登录
没有账号?点击注册
扫码二维码
CODEX微信公众号
添加微信
CODEX翻译客服
联系我们
400-136-8786
邮箱
Info@codex-trans.com